Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-cash Items (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-cash Items for 4 consecutive years, with $2409.0 as the latest value for Q3 2024.

  • On a quarterly basis, Non-cash Items fell 99.86% to $2409.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $2409.0, a 99.86% decrease, with the full-year FY2023 number at $373000.0, up 24455.63% from a year prior.
  • Non-cash Items was $2409.0 for Q3 2024 at Actinium Pharmaceuticals, up from $2121.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $2.2 million in Q3 2021 to a low of $415.0 in Q1 2022.
  • A 4-year average of $487224.8 and a median of $276000.0 in 2021 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: plummeted 99.97% in 2022, then skyrocketed 272784.01% in 2023.
  • Actinium Pharmaceuticals' Non-cash Items stood at $276000.0 in 2021, then plummeted by 99.45% to $1519.0 in 2022, then soared by 24455.63% to $373000.0 in 2023, then plummeted by 99.35% to $2409.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Non-cash Items are $2409.0 (Q3 2024), $2121.0 (Q2 2024), and $1797.0 (Q1 2024).